
Pfizer Inc. (NYSE:PFE) on Monday agreed to acquire Metsera, Inc. (NASDAQ:MTSR) to accelerate the next generation of medicines for obesity and cardiometabolic diseases.
The acquisition brings a portfolio of differentiated oral and injectable incretin, non-incretin, and combination therapy candidates.